![](/img/cover-not-exists.png)
Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt)
Nagafuji, Koji, Matsumura, Itaru, Shimose, Takayuki, Kawaguchi, Tatsuya, Kuroda, Junya, Nakamae, Hirohisa, Miyamoto, Toshihiro, Kadowaki, Norimitsu, Ishikawa, Jun, Imamura, Yutaka, Yamazaki, Hirohito,Language:
english
Journal:
International Journal of Hematology
DOI:
10.1007/s12185-019-02736-5
Date:
September, 2019
File:
PDF, 688 KB
english, 2019